Abstract

The purpose of the Tumor Procurement Core Facility is to coordinate collection and use of primary human cancer specimens from patients who undergo surgery or autopsy at the University of Oregon and VAMC. These tissues will support both basic and translational research studies of Cancer Center members. In addition to obtaining samples of tumor and adjacent normal tissue, an IRB approved consent exists to allow the drawing of a sample of blood for preparation of DNA. This core also prepares slides for histologic confirmation of the presence of tumor in the specimen. Collection of demographic, pathologic and clinical data is performed to facilitate correlative studies and this information is entered into a computerized data base. Centralized collection of tumor samples minimizes the biohazards involved in handling human tissues and allows coding of samples to insure anonymity of patients. Since the previous grant submission a charge back system has been established.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-03
Application #
6103199
Study Section
Project Start
1999-07-12
Project End
2000-05-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
Oregon Health and Science University
Department
Type
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239

  Publications

Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6
Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387

Showing the most recent 10 out of 277 publications